Patient guide · Respiratory medicine
Transbronchial biopsy, bronchoscopic biopsy of the lung parenchyma for diffuse lung disease.
Transbronchial lung biopsy (TBLB) uses biopsy forceps passed through the bronchoscope to sample the lung parenchyma — first-line for sarcoidosis, hypersensitivity pneumonitis and lung transplant rejection surveillance.
Reviewed by Pulse Atlas Editorial Board () · Last reviewed 2026-07-30 · Next review 2027-07-30 · 5 min read
Why it matters
- 01
A first-line ILD biopsy
Transbronchial lung biopsy is the workhorse first-line sampling technique for diffuse parenchymal lung disease.
- 02
Bronchoscopic, day-case
Performed under conscious sedation through the bronchoscope — most patients go home the same afternoon.
- 03
A clear onward pathway
Findings are discussed at an interstitial lung disease MDT so the plan is agreed before you leave the pathway.
Key facts
Transbronchial biopsy in six lines.
A quick, plain-English summary of the test, how it is done, and where it sits in the interstitial lung disease workup.
| Fact | Detail |
|---|---|
| Definition | Bronchoscopic biopsy of the lung parenchyma using forceps passed through the bronchoscope. |
| How it is performed | Bronchoscopy under conscious sedation, with local anaesthetic to the airway. |
| Image guidance | Fluoroscopy-guided to steer the forceps into the target segment safely. |
| Samples taken | Typically 4–6 biopsy samples from the affected lobe. |
| Where it sits in the pathway | Complements transbronchial cryobiopsy and EBUS-TBNA in the interstitial lung disease workup. |
| Why it matters | The foundation of the diagnostic workup for diffuse interstitial lung disease. |
How it is done
The pathway, step by step.
From respiratory consultation to MDT-agreed plan — how a transbronchial biopsy fits into the interstitial lung disease workup.
Phase 1 · Before
Consultation and workup
Phase 2 · On the day
Bronchoscopy under conscious sedation
Phase 3 · After
MDT and structured plan
- 01
Before
Respiratory consultation
A consultant respiratory review confirms the differential diagnosis, weighs the risks and agrees the sampling plan with you.
- 02
Before
Chest CT
A high-resolution CT of the chest identifies the target lobe and pattern of parenchymal disease.
- 03
Before
Coagulation check
Bloods including full blood count and clotting are checked, and antiplatelet or anticoagulant medication is paused where appropriate.
- 04
On the day
Bronchoscopy under conscious sedation
The bronchoscope is passed through the nose or mouth with local anaesthetic and light sedation — you remain awake but comfortable.
- 05
On the day
Transbronchial forceps biopsy
Biopsy forceps are advanced through the bronchoscope into the target segment and four to six parenchymal samples are taken.
- 06
On the day
Fluoroscopy confirmation
Live fluoroscopy confirms forceps position and is used to check for a post-procedure pneumothorax before you leave the suite.
- 07
After
Structured plan
Histology, radiology and clinical picture are pulled together at an interstitial lung disease MDT to agree a structured plan.
What it shows
What a transbronchial biopsy can diagnose.
The histology answers a specific set of interstitial and infiltrative lung questions — these are the conditions most often confirmed on TBLB.
-
Sarcoidosis (non-caseating granulomas)
The classic first-line indication — non-caseating granulomas on transbronchial biopsy support the diagnosis.
-
Hypersensitivity pneumonitis
Characteristic lymphocytic inflammation and poorly formed granulomas on parenchymal tissue.
-
Organising pneumonia
Buds of granulation tissue within alveolar ducts and alveoli, in keeping with organising pneumonia.
-
Lung transplant rejection
Surveillance transbronchial biopsy is the standard test for detecting acute rejection after lung transplantation.
-
Alveolar proteinosis
PAS-positive proteinaceous material filling the alveoli, diagnostic of pulmonary alveolar proteinosis.
-
Malignancy (peripheral nodule)
Sampling a peripheral lung nodule when a diagnosis cannot be obtained by other bronchoscopic techniques.
-
Pulmonary Langerhans cell histiocytosis
Cellular infiltrates with characteristic Langerhans cells confirming histiocytosis in a smoker.
-
Red flag: unexpected malignancy — urgent MDT
Unexpected malignant histology triggers an urgent lung-cancer MDT and rapid staging pathway.
Next steps
Treatment options after transbronchial biopsy.
What the pathway looks like once histology is back — from medical therapy through further sampling to MDT-led planning.
-
Corticosteroids (sarcoidosis, HP)
Systemic corticosteroids remain first-line for symptomatic sarcoidosis and progressive hypersensitivity pneumonitis.
-
Antigen avoidance (HP)
Identifying and removing the causative antigen is the single most effective intervention in hypersensitivity pneumonitis.
-
Immunosuppression
Steroid-sparing agents such as methotrexate, azathioprine or mycophenolate are used when disease is progressive or steroid-dependent.
-
Antifibrotic (nintedanib, pirfenidone)
Antifibrotic therapy slows lung-function decline in progressive fibrosing interstitial lung disease.
-
Cryobiopsy if inconclusive
Transbronchial cryobiopsy is offered when transbronchial forceps biopsy is non-diagnostic but a tissue diagnosis is still required.
-
Surgical lung biopsy (VATS)
Video-assisted thoracoscopic surgical biopsy is reserved for cases where less invasive sampling has not answered the question.
-
Respiratory follow-up
Serial lung-function testing and imaging under a consultant respiratory physician tracks response and progression.
-
MDT review
The interstitial lung disease MDT integrates clinical, radiological and pathological findings into a single agreed plan.
Red flags
When transbronchial biopsy findings need urgent action.
Presentations and complications that warrant same-day escalation rather than routine follow-up.
-
Unexpected malignancy
Unanticipated malignant histology triggers an urgent lung-cancer MDT and rapid staging.
-
Post-biopsy pneumothorax
A pneumothorax after transbronchial biopsy may need aspiration or chest-drain insertion — chest X-ray before discharge is standard.
-
Post-biopsy haemoptysis
Significant haemoptysis after biopsy warrants observation, and occasionally endobronchial haemostasis or interventional radiology.
-
Pulmonary hypertension
Significant pulmonary hypertension increases bleeding risk and may make transbronchial biopsy inadvisable.
-
Post-transplant rejection
Any suspicion of acute rejection on surveillance biopsy is discussed with the transplant team the same day.
-
Suspected TB (avoid biopsy first)
Where tuberculosis is strongly suspected, biopsy is generally deferred in favour of BAL, cultures and molecular testing.
-
Immunosuppressed with new nodule
A new pulmonary nodule in an immunosuppressed patient requires urgent workup for infection and malignancy in parallel.
-
Post-COVID progressive ILD
Progressive fibrotic change after COVID-19 warrants prompt respiratory review and consideration of antifibrotic therapy.
-
Post-radiotherapy new fibrosis
New fibrotic change outside the radiotherapy field, or unexpectedly rapid progression, needs specialist assessment.
Reading your report
A transbronchial biopsy report can look intimidating. It isn’t.
Whatever the finding, the report keeps to the same four parts.
A quiet reminder
The report is written for your doctor, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Indication and clinical context
Your details, the clinical question and the pre-procedure CT pattern that shaped the biopsy plan.
- 02 Technique
Bronchoscopy and sampling
The bronchoscopy, target segment, number of biopsy samples and use of fluoroscopy.
- 03 Findings
Histology and adequacy
Sample adequacy, histological pattern, granulomas, fibrosis, malignant cells or infective organisms.
- 04 Impression
The conclusion: read this first
The integrated diagnosis and the concrete next step, aligned with the interstitial lung disease MDT.
Frequently asked
Everything patients ask about transbronchial biopsy.
Quick answers on what the test is, how it is performed, what it can diagnose and what the results mean.
-
What is a transbronchial biopsy?
A transbronchial lung biopsy (TBLB) is a bronchoscopic technique where small biopsy forceps are passed through the bronchoscope and into the lung tissue itself to sample the parenchyma. It is used to diagnose diffuse interstitial lung diseases such as sarcoidosis, hypersensitivity pneumonitis and to monitor for rejection after lung transplantation.
-
How is a transbronchial biopsy performed?
It is performed as a day-case procedure under conscious sedation. A flexible bronchoscope is passed through the nose or mouth into the airways, local anaesthetic is applied, and biopsy forceps are advanced under fluoroscopy into the affected lobe. Four to six parenchymal samples are typically taken and sent for histology.
-
What conditions does it help diagnose?
It is a first-line tissue-sampling technique for sarcoidosis, hypersensitivity pneumonitis, organising pneumonia, pulmonary Langerhans cell histiocytosis, alveolar proteinosis and selected peripheral lung nodules. It is also the standard test for lung-transplant rejection surveillance.
-
What are the risks?
The two main risks are pneumothorax (a small collapse of the lung, typically in around one in twenty patients) and bleeding. Both are almost always managed conservatively. A chest X-ray is routinely performed before discharge to check for a pneumothorax.
-
How does it compare with cryobiopsy or surgical lung biopsy?
Transbronchial forceps biopsy gives small samples with a good safety profile and is the usual first step. Transbronchial cryobiopsy gives larger, better-preserved samples but with a slightly higher risk of bleeding and pneumothorax. Surgical lung biopsy (VATS) gives the largest samples but is the most invasive and is reserved for cases where less invasive sampling has not answered the question.
-
How quickly will I get the results?
Histology is typically available within one to two weeks. Your case is then discussed at an interstitial lung disease MDT, and a clinic appointment is arranged so a consultant respiratory physician can walk you through the findings and the agreed plan.
Sources
Where this guide comes from.
- British Thoracic Society. Interstitial lung disease guideline.
- European Respiratory Society. ERS guidance on interstitial lung disease and bronchoscopy.
- American Thoracic Society. Clinical practice guidelines on interstitial lung disease.
- NICE. Idiopathic pulmonary fibrosis and interstitial lung disease guidance.
Reviewed by Pulse Atlas Editorial Board (). Last reviewed 2026-07-30. Next review 2027-07-30.
Related tests
Looking for a different test?
-
Bronchoscopy
The parent procedure — direct visualisation of the airways under conscious sedation.
Learn more -
EBUS
Endobronchial ultrasound with fine-needle aspiration of mediastinal lymph nodes.
Learn more -
Lung biopsy
Percutaneous CT-guided or surgical lung biopsy where TBLB is not the right route.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Asthma
Related condition guide.
Learn more -
COPD
Related condition guide.
Learn more -
Continuous Positive Airway Pressure
Related treatment option.
Learn more -
Complementary Alternative Medicine
Related treatment option.
Learn more
In practice, in London
Getting transbronchial biopsy sorted in London, without the guesswork
With transbronchial biopsy, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. On the NHS, transbronchial biopsy typically sits behind a triage step and a wait that can stretch from a few weeks into months. In London’s private sector, the same appointment often lands within days. That speed matters when symptoms are disrupting work, sleep, or a plan you’d already committed to — and it’s the single most common reason people call us in the first place.
A private transbronchial biopsy pathway in London usually looks like this: an initial consultation, any diagnostics booked at a nearby facility (most within Zone 1 or 2), and a written report sent to you and your GP within a few days. The consultants we work with hold NHS posts alongside their private lists, which keeps the standards consistent across both settings. For transbronchial biopsy specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
The value of going through a concierge for transbronchial biopsy isn’t access — anyone with an insurer or a credit card can get a private appointment in London. The value is knowing which consultant reads this particular presentation best, which unit turns reports around fastest, and which pathway won’t hit a dead end if the findings point somewhere unexpected.